Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

VEMoS

Financiado

Virtual eye model system for personalised refractive surgery treatment

The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye... ver más

30/09/2023

VALCASADO SA

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

VALCASADO SA No se ha especificado una descripción o un objeto social para esta compañía.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-09-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 100%

8 Participantes

VALCASADO SA

1.43M€ | Lider

SOLENER SOLAR RENOVABLES

121.78K€ | Participante

CSO

761.90K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 46 meses Fecha Inicio: 2019-11-05
Fecha Fin: 2023-09-30

Líder del proyecto

VALCASADO SA

Presupuesto del proyecto 4M€

Descripción del proyecto The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye deficits. Vision impairments reduce the quality of life, affect economic and educational opportunities and increase the risk of death. This is particularly important for vulnerable groups such as elderly, children, workers and drivers. Overall, WHO reported that uncorrected vision was responsible for €241bn of productivity loss per year worldwide. Our innovative Virtual Eye Model System (VEMoS) is based on patented revolutionary ophthalmic diagnostic devices (CSO’s MS-39 tomographer/topographer and the unique open-field aberrometer), as well as on innovative simulation software developed by Vissum. Overall, our innovation provides personalised clinical-decision support based on each patient’s eye measurements and neural network simulations of post-surgery outcomes, improving surgery success and patient satisfaction rates. By combining CSO’s ophthalmic high-tech hardware design, manufacturing and commercialisation skills with Vissum’s refractive surgery and software development and independent clinical testing by CHUC and AUH, this project is expected to bring economic, social and health impacts, including progress towards achieving the EC action plan on personalised medicine ICPerMed. Our goal is to mature, scale-up and demonstrate the production of the VEMoS system, targeting ophthalmology clinics as clients, and with the aim to standardise refractive surgery decision making and revolutionise the refractive surgery field with personalised treatments. A successful VEMoS project will allow us to create measurable impacts on our companies, quantified as accumulated revenue of €145.3m in five years (2022-2026), equal to accumulated operating profit of €58.2m, creating 60 full time employments, and generating €37m in reduced customer costs.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores